Shilpa Medicare: Outcome of 38th AGM held on 23 September 2025
The announcement primarily concerns the outcome of the AGM and the passing of routine resolutions, which has a limited immediate impact.
All resolutions were passed with the required majority, indicating positive shareholder support.
* Shilpa Medicare Limited held its 38th Annual General Meeting (AGM) on 23 September 2025. * All resolutions mentioned in the AGM notice were passed with the requisite majority. * Key resolutions included: * Adoption of audited standalone and consolidated financial statements for the year ended 31 March 2025. * Declaration of dividend of ₹1.00 per equity share for the financial year ended March 31, 2025. * Re-appointment of Mr. Sharath Reddy Kalakota as a Whole Time Director. * Re-appointment of Dr. Anita Bandyopadhyay as an Independent Director. * Appointment of Mr. Ashraf Loutfy Abdelhamid Allam as an Independent Director. * Approval for revision in remuneration of Mr. Keshav Bhutada, Executive Director & CEO of Shilpa Pharma Lifesciences Ltd (SPLL). * Issue of Bonus Shares * Appointment of Mr. D.S Rao., Practicing Company Secretary, as Secretarial Auditors of the Company.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.